Introduction

Gender permeates the planning, commission, and resolution of criminal acts within the International Criminal Court’s jurisdiction. It is woven into perpetrators’ planning and commission of crimes, as well as victims’ (individual and collective) experience and recovery of acts committed against them. Accordingly, gender must be a central criterion in the group of independent experts’ review of the International Criminal Court (“ICC” or “the Court”) and the Rome Statute system. Laudably, the Rome Statute was among the first international treaties to extensively address sexual and gender-based violence. Moreover, from the beginning of her term ICC Prosecutor Fatou Bensouda has made it a priority to close the gender justice gap, as evidenced by her Policy Paper on Sexual and GenderBased Crimes, the first ever such policy for an international court or tribunal. Despite these foundational pillars and priorities, in the 18 years of the Court’s operation there has only been one standing conviction on sexual violence. This submission highlights avenues for improving gender justice at varying stages of a case. It identifies opportunities for progress regarding staffing and prosecutorial strategies on case selection, prioritization, and investigation that hinder access to justice in these cases. Until gender is mainstreamed throughout all stages of ICC cases, the Court will be limited in its capacity to deliver justice.

Download the Full Submission

Dear Acting Assistant Secretary O’Connell,

As members of the Inter-Agency Working Group on Reproductive Health in Crises (IAWG) we are writing to thank the U.S. government for its emergency response and humanitarian assistance to the COVID-19 global pandemic and to inquire about the inclusion of sexual and reproductive health supplies and services.

We appreciate PRM’s long-standing leadership in addressing the sexual and reproductive health needs of people around the world through U.S. global health and humanitarian funding and programs. As you know, women and girls, and others who face stigma and discrimination, continue to have sexual and reproductive health needs even as crises unfold. These can include pregnancy, the desire to become pregnant, avoid unwanted pregnancy, avoid sexually transmitted infections, and prevent and respond to gender-based violence. During crises, some of these needs are more acute. We know that gender-based violence increases during crises and that gender-based violence increases the risk of acquiring HIV.

Download the Letter

Dear Acting Administrator Barsa,

As members of the Inter-Agency Working Group on Reproductive Health in Crises (IAWG) we are writing to thank the U.S. government for its emergency response and humanitarian assistance to the COVID-19 global pandemic and to inquire about the inclusion of sexual and reproductive health supplies and services.

We appreciate USAID’s long-standing leadership in addressing the sexual and reproductive health needs of people around the world through U.S. global health and humanitarian funding and programs. As you know, women and girls, and others who face stigma and discrimination, continue to have sexual and reproductive health needs even as crises unfold. These can include pregnancy, the desire to become pregnant, avoid unwanted pregnancy, avoid sexually transmitted infections, and prevent and respond to gender-based violence. During crises, some of these needs are more acute. We know that gender-based violence increases during crises and that gender-based violence increases the risk of acquiring HIV.

Download the Letter

Dear Dr. Woodcock,

We, the undersigned, respectfully request the U.S. Food and Drug Administration (FDA) reconsider its limitation of the recently released Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency (Docket FDA-2020-D-1106).

The policy waives certain Risk Evaluation and Mitigation Strategies (REMS) requirements – namely laboratory tests and imaging – but not others. The requirements that certain drugs must be dispensed in-person by certain medical professionals provides similar burdens and risks to patients and providers as the waived requirements. Therefore, we request that in-person dispensation requirements, specifically for mifepristone, be included in this policy as temporarily waived.

Download the Letter